| Literature DB >> 30792474 |
Dong-Ling Yu1, Yuan-Lin Ma1, Zu-Guo Yu2,3.
Abstract
More and more research works have indicated that microRNAs (miRNAs) play indispensable roles in exploring the pathogenesis of diseases. Detecting miRNA-disease associations by experimental techniques in biology is expensive and time-consuming. Hence, it is important to propose reliable and accurate computational methods to exploring potential miRNAs related diseases. In our work, we develop a novel method (BRWHNHA) to uncover potential miRNAs associated with diseases based on hybrid recommendation algorithm and unbalanced bi-random walk. We first integrate the Gaussian interaction profile kernel similarity into the miRNA functional similarity network and the disease semantic similarity network. Then we calculate the transition probability matrix of bipartite network by using hybrid recommendation algorithm. Finally, we adopt unbalanced bi-random walk on the heterogeneous network to infer undiscovered miRNA-disease relationships. We tested BRWHNHA on 22 diseases based on five-fold cross-validation and achieves reliable performance with average AUC of 0.857, which an area under the ROC curve ranging from 0.807 to 0.924. As a result, BRWHNHA significantly improves the performance of inferring potential miRNA-disease association compared with previous methods. Moreover, the case studies on lung neoplasms and prostate neoplasms also illustrate that BRWHNHA is superior to previous prediction methods and is more advantageous in exploring potential miRNAs related diseases. All source codes can be downloaded from https://github.com/myl446/BRWHNHA .Entities:
Year: 2019 PMID: 30792474 PMCID: PMC6385311 DOI: 10.1038/s41598-019-39226-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Predicting outcomes for MIDPE, HAMDA, BRWH and BRWHNHA by the five-fold cross-validation.
| Diseases name | Number of related miRNAs | The average AUC | |||
|---|---|---|---|---|---|
| MIDPE[ | HAMDA[ | BRWH[ | BRWHNHA | ||
| Breast Neoplasms | 202 | 0.813 | 0.821 | 0.812 | |
| Carcinoma, Hepatocellular | 214 | 0.777 | 0.791 | 0.776 | |
| Carcinoma, Non-Small-Cell Lung | 95 | 0.859 | 0.867 | 0.857 | |
| Carcinoma, Renal Cell | 107 | 0.814 | 0.822 | 0.812 | |
| Carcinoma, Squamous Cell | 80 | 0.874 | 0.875 | 0.882 | |
| Colonic Neoplasms | 78 | 0.855 | 0.866 | 0.853 | |
| Colorectal Neoplasms | 147 | 0.819 | 0.838 | 0.824 | |
| Endometriosis | 62 | 0.815 | 0.814 | 0.841 | |
| Esophageal Neoplasms | 74 | 0.794 | 0.793 | 0.793 | |
| Glioblastoma | 96 | 0.805 | 0.825 | 0.801 | |
| Glioma | 71 | 0.868 | 0.863 | 0.874 | |
| Head and Neck Neoplasms | 64 | 0.872 | 0.870 | 0.881 | |
| Heart Failure | 120 | 0.802 | 0.800 | 0.807 | |
| Leukemia, Myeloid, Acute | 64 | 0.857 | 0.852 | 0.858 | |
| Lung Neoplasms | 132 | 0.906 | 0.919 | 0.906 | |
| Medulloblastoma | 62 | 0.801 | 0.807 | 0.798 | |
| Melanoma | 141 | 0.823 | 0.838 | 0.825 | |
| Ovarian Neoplasms | 114 | 0.866 | 0.902 | 0.887 | |
| Pancreatic Neoplasms | 99 | 0.905 | 0.907 | 0.902 | |
| Prostatic Neoplasms | 118 | 0.833 | 0.857 | 0.831 | |
| Stomach Neoplasms | 173 | 0.782 | 0.802 | 0.783 | |
| Urinary Bladder Neoplasms | 92 | 0.842 | 0.833 | ||
Figure 1Recall-precision curves of breast neoplasm and lung neoplasm by five-fold cross-validation.
Pairwise comparison between BRWHNHA and another method by paired t-test on the AUC of prediction.
| Method | MIDPE[ | HAMDA[ | BRWH[ |
|---|---|---|---|
| P-value | 2.41E-07 | 1.71E-02 | 4.00E-08 |
Effects of parameters λ, α, r, l on prediction performance of BRWHNHA.
|
| Average AUC |
| Average AUC |
|---|---|---|---|
| 0 | 0.748654 | 0 | 0.804929 |
| 0.1 | 0.814260 | 0.1 | 0.844848 |
| 0.2 | 0.844524 | 0.2 | 0.853413 |
| 0.3 | 0.852676 | 0.3 | 0.856242 |
| 0.4 | 0.855220 | 0.4 |
|
| 0.5 | 0.856081 | 0.5 | 0.855095 |
| 0.6 |
| 0.6 | 0.853919 |
| 0.7 | 0.856418 | 0.7 | 0.850477 |
| 0.8 | 0.856146 | 0.8 | 0.848039 |
| 0.9 | 0.855824 | 0.9 | 0.847697 |
| 1 | 0.855415 | 1 | 0.847478 |
|
|
|
|
|
| 0 | 0.846267 | 0 | 0.856710 |
| 1 | 0.852731 | 1 |
|
| 2 |
| 2 | 0.853561 |
| 3 | 0.856814 | 3 | 0.846865 |
| 4 | 0.856555 | 4 | 0.846626 |
| 5 | 0.856371 | 5 | 0.846505 |
The first 50 potential miRNAs associated with lung neoplasms predicted by BRWHNHA.
| Rank | miRNAs | Evidence | Rank | miRNAs | Evidence |
|---|---|---|---|---|---|
| 1 | hsa-mir-20b | DB | 26 | hsa-mir-302f | DB |
| 2 | hsa-mir-15b | DB | 27 | hsa-mir-1258 | DB |
| 3 | hsa-mir-34b | DB | 28 | hsa-mir-1305 | DB |
| 4 | hsa-mir-21 | DB, MD | 29 | hsa-mir-140 | DB, MD |
| 5 | hsa-mir-200b | DB, MD | 30 | hsa-mir-106a | DB, MD |
| 6 | hsa-mir-29b | DB, MD | 31 | hsa-mir-219 | DB, MD |
| 7 | hsa-mir-146a | DB, MD | 32 | hsa-mir-1827 | PMID:21676885 |
| 8 | hsa-mir-7i | DB | 33 | hsa-mir-675 | DB |
| 9 | hsa-mir-1236 | DB | 34 | hsa-mir-485 | DB |
| 10 | hsa-mir-30e | DB, MD | 35 | hsa-mir-105 | DB |
| 11 | hsa-let-200a | DB, MD | 36 | hsa-mir-92b | DB |
| 12 | hsa-mir-885 | DB | 37 | hsa-mir-1323 | DB |
| 13 | hsa-let-147b | DB | 38 | hsa-mir-135a | DB |
| 14 | hsa-let-10a | DB | 39 | hsa-mir-98 | DB, MD |
| 15 | hsa-mir-198 | DB, MD | 40 | hsa-mir-137 | DB |
| 16 | hsa-let-100 | DB | 41 | hsa-mir-27a | DB |
| 17 | hsa-mir-212 | DB, MD | 42 | hsa-mir-235 | DB |
| 18 | hsa-mir-181d | DB | 43 | hsa-mir-450b | DB |
| 19 | hsa-mir-217 | DB | 44 | hsa-mir-495 | DB |
| 20 | hsa-mir-204 | DB, MD | 45 | hsa-mir-18a | DB, MD |
| 21 | hsa-mir-374b | DB | 46 | hsa-mir-1915 | DB |
| 22 | hsa-mir-133a | DB | 47 | hsa-mir-101 | DB, MD |
| 23 | hsa-mir-200 | Unconfirmed | 48 | hsa-mir-23a | DB |
| 24 | hsa-mir-106b | DB | 49 | hsa-mir-1207 | DB |
| 25 | hsa-mir-194 | DB | 50 | hsa-mir-337 | DB |
*The databases dbDEMC and mir2disease are respectively represented as DB and MD.
The first 50 potential miRNAs associated with prostate neoplasms predicted by BRWHNHA.
| Rank | miRNAs | Evidence | Rank | miRNAs | Evidence |
|---|---|---|---|---|---|
| 1 | hsa-mir-154 | DB | 26 | hsa-mir-137 | PMID:26461474 |
| 2 | hsa-mir-189 | DB | 27 | hsa-mir-134 | DB |
| 3 | hsa-mir-19a | DB | 28 | hsa-mir-30a | DB, MD |
| 4 | hsa-mir-29b | DB, MD | 29 | hsa-mir-138 | PMID:28741117 |
| 5 | hsa-mir-21 | DB, MD | 30 | hsa-mir-302a | DB |
| 6 | hsa-mir-199b | DB, MD | 31 | hsa-mir-450b | DB |
| 7 | hsa-mir-141 | DB, MD | 32 | hsa-mir-495 | DB |
| 8 | hsa-mir-10a | DB, MD | 33 | hsa-mir-26a | DB, MD |
| 9 | hsa-mir-181 | DB | 34 | hsa-mir-20a | DB, MD |
| 10 | hsa-mir-885 | DB | 35 | hsa-mir-139 | DB |
| 11 | hsa-let-7d | DB, MD | 36 | hsa-mir-107 | DB |
| 12 | hsa-mir-149 | DB, MD | 37 | hsa-mir-148b | DB |
| 13 | hsa-let-7e | DB | 38 | hsa-mir-2355 | DB |
| 14 | hsa-let-7f | DB, MD | 39 | hsa-mir-302b | DB |
| 15 | hsa-mir-195 | DB, MD | 40 | hsa-mir-337 | DB |
| 16 | hsa-let-7g | DB, MD | 41 | hsa-mir-624 | DB |
| 17 | hsa-mir-302f | Unconfirmed | 42 | hsa-mir-214 | DB, MD |
| 18 | hsa-mir-23b | DB, MD | 43 | hsa-mir-205 | DB, MD |
| 19 | hsa-mir-199a | DB, MD | 44 | hsa-mir-1286 | Unconfirmed |
| 20 | hsa-mir-1915 | Unconfirmed | 45 | hsa-mir-340 | DB |
| 21 | hsa-mir-1258 | DB | 46 | hsa-mir-1275 | DB |
| 22 | hsa-mir-675 | DB | 47 | hsa-mir-136 | DB |
| 23 | hsa-mir-4257 | Unconfirmed | 48 | hsa-mir-218 | DB, MD |
| 24 | hsa-mir-18a | DB | 49 | hsa-mir-498 | DB, MD |
| 25 | hsa-mir-101 | DB, MD | 50 | hsa-mir-301b | PMID:29744254 |
*The databases dbDEMC and mir2disease are respectively represented as DB and MD.
Figure 2Hierarchical DAG graph of Lung neoplasms.
Figure 3The HeatS (a–c) and ProbS (d–f) algorithms at work on the bipartite miRNA-disease network. Disease are shown as green squares and dark green squares is a given disease, miRNAs are shown as red circles.
Figure 4Flowchart of potential miRNA-disease association prediction based on the computational model of BRWHNHA.